On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), At the Forefront of the Psychedelic Renaissance

  • Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposes
  • The prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelics
  • The 21st century has seen a surge in psychedelics research, a critical factor that has initiated a renaissance in this industry
  • Tryp Therapeutics remains at the forefront of this renaissance with its commitment to identifying and developing clinical-stage compounds for diseases with high unmet medical needs, like Fibromyalgia and Eating Disorder

Since its inception, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has remained committed to identifying and developing clinical-stage compounds for diseases with high unmet medical needs. It seeks to achieve this through accelerated regulatory pathways, and its main program, Psilocybin-For-Neuropsychiatric Disorders (PFN(TM)) program, is a testament to that.

With PFN, Tryp focuses on developing psilocybin-based drug therapies for the treatment of specific neuropsychiatric disorders. So far, psilocybin has shown various advantages over mainstream alternatives already in the market. These benefits include natural blood-brain barrier penetration, increased efficacy, enhanced safety and toxicity profiles and reduced risk of abuse and addiction (https://ibn.fm/JUoAz).

Given what Tryp has achieved so far, it is easy to see the potential that psychedelics hold in the treatment of psychological ailments along with other medical conditions with high unmet needs. Additionally, it is easy for one to appreciate the strides that have been taken and the role that companies such as Tryp are making to demystify the usage of these substances for medical purposes.

Historically, psilocybin has been used in many specific cultures, not just for medicinal purposes but also to reach an altered state of consciousness. There is evidence of the Aztecs consuming mushrooms and even individuals in the Americas using psychedelics in specific ceremonies. In North Africa and Europe, cave paintings that date back to 4000 BC show psilocybin, thus proving the usage of these substances in particular rituals and medicinal purposes (https://ibn.fm/3zyUF).

Fast forward to the prohibition era, which saw great strides in psychedelics research and stringent measures from governments and the United Nations that would, ultimately, see a ban on the possession, sale, and manufacture of psychedelics. The late 19th and early 20th centuries saw Arthur Heffter isolate mescaline from the peyote cactus and Albert Hofmann synthesizing LSD, among other huge milestones. However, the late 20th century saw the UN declaring LSD, DMT, and MDMA as controlled substances.

In the 21st century, the scientific community has proven the potential of psychedelics to rewire or repair circuits in the brain. In 2020, research conducted by scientists in Spain showed that DMT could stimulate the production of new brain cells. That same year, Santa Cruz decriminalized psychedelic substances, including peyote, ayahuasca, and psilocybin (https://ibn.fm/Nk3ta).

Currently, Tryp continues to contribute to the ongoing conversation regarding the use of psychedelics in the field of medicine. Additionally, bringing light to psilocybin usage in chronic pain indications. With its three strategic initiatives- develop, protect and monetize- Tryp remains committed to utilizing FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to not only shorten the approval timelines but also lower the cost of development programs (https://ibn.fm/6I1oK). This is in a bid to bring psychedelic treatments closer to the people. It also seeks to grow an industry that has been dormant for decades for all the wrong reasons.

The psychedelic medical market is still in its early days. There is still a lot that needs to be done. However, one thing that remains true is the industry’s vast potential to transform healthcare. It is projected that by 2027, the medicinal psychedelics market will be valued at $6.8 billion, up from $2 billion in 2019. Experts have even noted that it could eventually become a $100 billion market. Tryp Therapeutics is capitalizing on this potential and leading the accompanying transformation. By doing so, Tryp is stamping its position as a leader in the ongoing psychedelic renaissance.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF 

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered